Pathophysiology of DKD in T2D: Traditional Teaching and New Insights

Apr 27, 2022 | DKD

2) This #accredited #tweetorial series on the foundations of #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.— @CKD_ce (@ckd_ce)...

Optimizing Interprofessional & Multidisciplinary Care & Medical Therapy for Patients with DKD

Apr 7, 2022 | DKD

1) Welcome to our new #tweetorial on optimizing #interprofessional & #multidisciplinary care & medical therapy for patients with #DKD. I am Sophia Ambruso DO, @sophia_kidney, from @CU_Kidney. 2) This #accredited #tweetorial series on #kidneydisease #DKD...

Optimal Deployment of the Multidisciplinary, Interprofessional Team to Ensure Appropriate Care of Patients with T2D and Cardiac Disease

Mar 24, 2022 | DKD

1) Welcome to a new #accredited #tweetorial on optimal deployment of the multidisciplinary, interprofessional team to ensure appropriate care of patients with type 2 diabetes #T2D & cardiac disease, #CaReMe #FOAMed. This program is accredited for 0.5h 🆓CE/#CME...

Commentary on New ADA-KDIGO Consensus Statement on Diabetic Kidney Disease

Mar 14, 2022 | DKD

1) Welcome to a new #accredited #tweetorial from our good friends and #diabetes experts @GoggleDocs, specifically @drkevinfernando, @drpatrickholmes, & @AmarPut. They have put their 🗣️s together to provide us with a summary of the first-ever consensus statement...

Risk Stratification: Identifying the Patient with T2D and DKD Most at Risk for Rapid Progression to Advanced CKD

Mar 9, 2022 | DKD

2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.— @CKD_ce (@ckd_ce) August 31, 2022 4)...

Commonly Used Meds in Patients with or at Risk for DKD Progression: 3d Generation MRAs, GLP-1 RAs, DPP-4i’s

Feb 23, 2022 | DKD

1) Welcome to our new #accredited #tweetorial on #mechanismofaction & impact of meds commonly used in patients with or at risk for #DKD progression: #MRAs, #GLP-1 receptor agonists & #DPP-4 inhibitors. I am Sophia Ambruso DO, @sophia_kidney, from @CU_Kidney....